Piramal Pharma Announces Unaudited Financial Results for Quarter Ended Sep 30, 2025
Piramal Pharma Limited's Board approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. Standalone PAT ₹196.33 crore. Consolidated Net loss ₹99.22 crore.
Quarterly results announcements generally have a medium impact as they provide insights into the company's performance and can influence investor decisions.
The announcement is a factual disclosure of the company's quarterly financial results, which include both positive (profit in standalone results) and negative (loss in consolidated results) aspects, leading to an overall neutral sentiment.
* Piramal Pharma Limited's Board approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, on November 5, 2025. * Standalone Financial Results: * Revenue from operations stood at ₹1,127.26 crore for the quarter ended September 30, 2025. * Net Profit after tax was ₹196.33 crore. * Consolidated Financial Results: * Revenue from operations was ₹2,043.72 crore for the quarter ended September 30, 2025. * Net loss after tax was ₹99.22 crore. * The results have been reviewed by the Audit Committee and the Statutory Auditors.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.